Cargando…
Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours
Individuals with germline mutations in the tumour suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation (aCGH) a...
Autores principales: | Rajan, Neil, Elliott, Richard, Clewes, Oliver, Mackay, Alan, Reis-Filho, Jorge S., Burn, John, Langtry, James, Sieber-Blum, Maya, Lord, Christopher J., Ashworth, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175103/ https://www.ncbi.nlm.nih.gov/pubmed/21552290 http://dx.doi.org/10.1038/onc.2011.133 |
Ejemplares similares
-
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial
por: Cranston, Amy, et al.
Publicado: (2017) -
Overexpression of MYB drives proliferation of CYLD‐defective cylindroma cells
por: Rajan, Neil, et al.
Publicado: (2016) -
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial
por: Danilenko, Marina, et al.
Publicado: (2018) -
The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling
por: Rajan, Neil, et al.
Publicado: (2014) -
Tracking tumor kinetics in patients with germline CYLD mutations
por: Brown, Sarah, et al.
Publicado: (2018)